These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25180059)

  • 21. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
    Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
    Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung.
    Borrelli N; Giannini R; Proietti A; Alì G; Pelliccioni S; Niccoli C; Lucchi M; Melfi F; Mussi A; Basolo F; Fontanini G
    Lung Cancer; 2013 Sep; 81(3):377-381. PubMed ID: 23891510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous analysis of
    Novaes LAC; Sussuchi da Silva L; De Marchi P; Cavagna RO; de Paula FE; Zanon MF; Evangelista AF; Albino da Silva EC; Duval da Silva V; Leal LF; Reis RM
    Transl Lung Cancer Res; 2021 Jan; 10(1):292-303. PubMed ID: 33569313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients.
    Wang WT; Li Y; Ma J; Chen XB; Qin JJ
    Asian Pac J Cancer Prev; 2014; 15(9):3927-32. PubMed ID: 24935562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with
    Digumarthy SR; Mendoza DP; Lin JJ; Rooney M; Do A; Chin E; Yeap BY; Shaw AT; Gainor JF
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32183422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
    Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
    Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.
    Zhang X; Zhang S; Yang X; Yang J; Zhou Q; Yin L; An S; Lin J; Chen S; Xie Z; Zhu M; Zhang X; Wu YL
    Mol Cancer; 2010 Jul; 9():188. PubMed ID: 20624322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
    Cai C; Tang Y; Li Y; Chen Y; Tian P; Wang Y; Gong Y; Peng F; Zhang Y; Yu M; Wang K; Zhu J; Lu Y; Huang M
    Lung Cancer; 2021 Feb; 152():104-108. PubMed ID: 33444901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
    Cao H; Zheng J; Zhao J; Guo XJ; Zhou JY; Ding W; Zhou JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):120-125. PubMed ID: 32062881
    [No Abstract]   [Full Text] [Related]  

  • 30. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
    J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements.
    Wu S; Wang J; Zhou L; Su D; Liu Y; Liang X; Zhang S; Zeng X
    Thorac Cancer; 2015 Jul; 6(4):413-20. PubMed ID: 26273395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
    Kohno T; Nakaoku T; Tsuta K; Tsuchihara K; Matsumoto S; Yoh K; Goto K
    Transl Lung Cancer Res; 2015 Apr; 4(2):156-64. PubMed ID: 25870798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung.
    Doval D; Prabhash K; Patil S; Chaturvedi H; Goswami C; Vaid A; Desai S; Dutt S; Veldore V; Jambhekar N; Mehta A; Hazarika D; Azam S; Gawande S; Gupta S
    Onco Targets Ther; 2015; 8():117-23. PubMed ID: 25609979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of multigene detection in patients with advanced lung adenocarcinoma using cytological specimens.
    Ma Y; Du Y; Wang R; Ji X; Wu J; Liu Y; Guo X; Zhang Y
    Pathol Res Pract; 2020 Aug; 216(8):153036. PubMed ID: 32703499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.
    Wu C; Zhao C; Yang Y; He Y; Hou L; Li X; Gao G; Shi J; Ren S; Chu H; Zhou C; Zhang J; Schmid-Bindert G
    J Thorac Oncol; 2015 May; 10(5):778-783. PubMed ID: 25629635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance Mechanisms to Targeted Therapies in
    McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
    Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
    Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
    Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
    Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
    Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a high-throughput and sensitive assay of fusion genes in lung cancer by array-based MALDI-TOFMS.
    Wu HT; Li K; Wang G; Yang XX; Zhu A; Xu XP; Li M; Wu YS; Liu TC
    RSC Adv; 2018 Aug; 8(49):27935-27945. PubMed ID: 35548167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.